Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Alejandro Marinos Velarde, MD	Faculty	1. Incyte	1. Non-CE Consulting	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Alexandra Mendoza, MS, PA-C	Faculty	No relevant financial disclosures	N/A	N/A
Anita Stokes, CRNP	Faculty	No relevant financial disclosures	N/A	N/A
Anna Hawkshead	ASTCT Staff and Planning Committee	No relevant financial disclosures	N/A	N/A
Ashley Smeaton, MHA	TFF Staff	No relevant financial disclosures	N/A	N/A
Chelsea Honstain, DNP	Planning Committee Co- Chair and Faculty	No relevant financial disclosures	N/A	N/A
Cherian Verghese, MD, MPH	Faculty	1. ADC Therapeutics	1. Non-CE Consulting	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Christina Ullrich, MD, MPH	Faculty	No relevant financial disclosures	N/A	N/A
Christopher Dandoy, MD, MS	Faculty	Incyte Alexion, Omeros	Non-CE Speakers Bureau Anorarium	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Courtney Culbertson, MSN, APRN-CPNP- AC, CPHON, BMT-CN	Faculty	No relevant financial disclosures	N/A	N/A
David Porter, MD	Faculty	1. Angiocrine Bioscience, Bristol Myers Squibb, Kite/Gilead, Mirror Biologics, Novartis, Sana Biotechnology, Verismo Therapeutics	1. Non-CE Consulting	The following financial conflicts of interest were mitigated by the relationship ending: Kite/Gilead ended in January 2025 BMS ended in June 2023 Verismo ended in November 2023 Novartis ended in August 2024 and December 2024 Angiocrine Bioscience ended in December 2023
		2. Bristol MyersSquibb, KyvernaTherapeutics, Novartis3. Novartis (University of Pennsylvania licensed to Novartis)	2. Contract Research 3. Receipt of Intellectual Property Rights / Patent Holder	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
		4. Genentech	4. Stock ownership of a publicly traded company	
		5. Novartis	5. Royalty	
Elizabeth (Bettina) Zerante, MS, AGACNP-BC	Planning Committee Co- Chair	No relevant financial disclosures	N/A	N/A

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Emily Bauer, DNP, APRN, AGACNP-BC	Faculty	No relevant financial disclosures	N/A	N/A
Ghadir Sasa, MD	Faculty	1. Mesoblast	1. Non-CE Consulting	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Gianni Scappaticci, PharmD, BCOP	Faculty	No relevant financial disclosures	N/A	N/A
Heather Tarbox, MPH	TFF Staff	No relevant financial disclosures	N/A	N/A
Jessica Spruit, DNP, CPNP-AC, FAANP	Faculty	No relevant financial disclosures	N/A	N/A
Jordan Leal, DNP, APRN-NP, BMTCN	Faculty	No relevant financial disclosures	N/A	N/A
Katherine Sellers, MPAS, PA-C	Faculty	1. Incyte, Janssen, Sanofi	1. Non-CE Consulting	The following relationships have been mitigated by ending within the past 24 months: • Incyte, Janssen, and Sanofi
				Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Katie Finnigan, MS, RD, PA-C	Faculty	No relevant financial disclosures	N/A	N/A
Kyle Brownback, MD	Faculty	1. Sanofi	1. Non-CE Consulting	The following relationship has been mitigated by ending: • Sanofi in June 2024
				Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
				biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Liza Rodriguez, APRN, AOCNP	Planning Committee Co- Chair	1. Incyte	1. Non-CE Consulting (Advisory Board)	All final review and planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted planning committee members.
Michelle Skinner, DNP, APRN, CPNP-AC	Faculty and Planning Committee	No relevant financial disclosures	N/A	N/A
Miriam Garcia, DO	Faculty	No relevant financial disclosures	N/A	N/A
Myrshia L. Hunter, PA-C	Faculty	No relevant financial disclosures	N/A	N/A
Nahid Suleman, MD	Planning Committee	No relevant financial disclosures	N/A	N/A
Nebu Koshy	Faculty	No relevant financial disclosures	N/A	N/A
Nicolas Parnell, MD	Faculty and Planning Committee	No relevant financial disclosures	N/A	N/A
Praveen Ramakrishnan, MD, MS, MBA, FACP	Faculty	1. Acrotech Biopharma, ADC Therapeutics, BMS, Ipsen, Kite/Gilead, Ono Pharma, Regeneron, Sobi	1. Non-CE Consulting	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Samuel John, MD	Faculty	1. Adaptimmune, Novartis	1. Contract Research	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
		2. Inventor/Patent	2. Receipt of	
		Holder – Anti-LILRB4	intellectual	
		CAR-T cell	property	
			rights/patent	
			holder	
Sara Pirzadeh-Miller,	Faculty	No relevant financial	N/A	N/A
MS, CGC		disclosures		
Shatha Farhan, MD	Faculty	No relevant financial	N/A	N/A
		disclosures		
Siddhartha Ganguly,	Faculty	1. Bristol Myers	1. Non-CE	Content was reviewed by a non-conflicted member of the
MD		Squibb	Consulting	planning committee to ensure that it is not commercially
				biased, is fair-balanced, and is based on scientific evidence
		2. Karyopharm	2. Non-CE	and/or clinical reasoning.
			Speakers Bureau	
Vivian Irizarry Gatell	Faculty	No relevant financial	N/A	N/A
		disclosures		
Zainab Shahid, MD	Faculty	1. Aseptiscope	1. Non-CE	The following relationship has been mitigated by ending:
			Consulting,	Aseptiscope in November 2024
			Advisory Board	
			Attendance	Content was reviewed by a non-conflicted member of the
				planning committee to ensure that it is not commercially
				biased, is fair-balanced, and is based on scientific evidence
				and/or clinical reasoning.
Zandra Rivera, APP	Planning	No relevant financial	N/A	N/A
	Committee Co-	disclosures		
	Chair			